These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1494357)
21. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Zhanel GG; Saunders DG; Hoban DJ; Karlowsky JA Antimicrob Agents Chemother; 2001 Jul; 45(7):2018-22. PubMed ID: 11408217 [TBL] [Abstract][Full Text] [Related]
22. Kinetic study of antifungal activity of amphotericin B, 5-fluorocytosine and ketoconazole against clinical yeast isolates using liquid-phase turbidimetry. Dei-Cas E; Dujardin L; Ribeiro Pinto ME; Ajana F; Fruit J; Poulain D; Camus D; Vernes A Mycoses; 1991; 34(3-4):167-72. PubMed ID: 1749396 [TBL] [Abstract][Full Text] [Related]
23. Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole. Hoeprich PD; Huston AC J Infect Dis; 1975 Aug; 132(2):133-41. PubMed ID: 1099147 [TBL] [Abstract][Full Text] [Related]
24. Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans. Warnock DW; Johnson EM; Burke J; Pracharktam R J Antimicrob Chemother; 1989 Jun; 23(6):837-47. PubMed ID: 2547749 [TBL] [Abstract][Full Text] [Related]
25. Intracellular killing of Candida albicans by human neutrophils is potentiated by exposure to combinations of amphotericin B and 5-fluorocytosine. Richardson MD; Paton M; Shankland GS Mycoses; 1991; 34(5-6):201-4. PubMed ID: 1795714 [TBL] [Abstract][Full Text] [Related]
26. New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve. Chryssanthou E; Cars O; Sjölin J Antimicrob Agents Chemother; 2002 Dec; 46(12):4016-8. PubMed ID: 12435715 [TBL] [Abstract][Full Text] [Related]
27. Post-antifungal effect and adhesion to buccal epithelial cells of oral Candida dubliniensis isolates subsequent to limited exposure to amphotericin B, ketoconazole and fluconazole. Ellepola AN; Chandy R; Khan ZU J Investig Clin Dent; 2015 Aug; 6(3):186-92. PubMed ID: 24850753 [TBL] [Abstract][Full Text] [Related]
28. In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Shadomy S; Wagner G; Espinel-Ingroff E; Davis BA Antimicrob Agents Chemother; 1975 Aug; 8(2):117-21. PubMed ID: 1101814 [TBL] [Abstract][Full Text] [Related]
29. Strong correlation between the antifungal effect of amphotericin B and its inhibitory action on germ-tube formation in a Candida albicans URA⁺ strain. Guirao-Abad JP; González-Párraga P; Argüelles JC Int Microbiol; 2015 Mar; 18(1):25-31. PubMed ID: 26415664 [TBL] [Abstract][Full Text] [Related]
30. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients. Paniagua GL; Monroy E; Negrete E; Vaca S Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773 [TBL] [Abstract][Full Text] [Related]
32. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. Conly J; Rennie R; Johnson J; Farah S; Hellman L J Infect Dis; 1992 Apr; 165(4):761-4. PubMed ID: 1285732 [TBL] [Abstract][Full Text] [Related]
33. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Bulo AN; Bradley SF; Kauffman CA Mycoses; 1989 Jan; 32(1):46-52. PubMed ID: 2747742 [TBL] [Abstract][Full Text] [Related]
34. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species. Bulo AN; Bradley SF; Kauffman CA Mycoses; 1989 Mar; 32(3):151-7. PubMed ID: 2733727 [TBL] [Abstract][Full Text] [Related]
35. Postantifungal effect and effects of sub-MIC concentrations on previously treated Candida sp. influence of growth phase. García MT; Llorente MT; Mínguez F; Prieto J J Infect; 2002 Nov; 45(4):263-7. PubMed ID: 12423615 [TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction of miconazole and fluconazole at sub-MIC level on Candida albicans. Mikami Y; Takahashi A; Yazawa K; Terao K; Ueno Y Mycoses; 1992; 35(11-12):321-7. PubMed ID: 1302808 [TBL] [Abstract][Full Text] [Related]
37. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. Calhoun DL; Roberts GD; Galgiani JN; Bennett JE; Feingold DS; Jorgensen J; Kobayashi GS; Shadomy S J Clin Microbiol; 1986 Feb; 23(2):298-301. PubMed ID: 3517051 [TBL] [Abstract][Full Text] [Related]
38. Effects of two different growth media on the postantifungal effect induced by polyenes on Candida species. Shu M; Ellepola AN; Samaranayake LP J Clin Microbiol; 2001 Jul; 39(7):2732-5. PubMed ID: 11427609 [TBL] [Abstract][Full Text] [Related]
39. In vitro activity of amphotericin B, flucytosine and fluconazole against yeasts causing bloodstream infections. Berenguer J; Fernández-Baca V; Sánchez R; Bouza E Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):362-5. PubMed ID: 7649205 [TBL] [Abstract][Full Text] [Related]
40. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. Barchiesi F; Di Francesco LF; Compagnucci P; Arzeni D; Giacometti A; Scalise G J Antimicrob Chemother; 1998 Jan; 41(1):59-65. PubMed ID: 9511038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]